Acurx Pharmaceuticals, Inc. (ACXP) — Current Report

AI-Powered SEC Filing Analysis

← All ACXP filings
Latest Current Report Filed: 2026-04-16

Key Insights

  • Acurx Pharmaceuticals has raised approximately $2.5 million in a registered direct offering, which it intends to use for working capital and general corporate purposes.
  • The company has issued pre-funded warrants and Series H warrants to investors, providing additional financing and potential future equity.
  • Acurx has agreed to certain restrictions on future equity issuances and entered into an engagement letter with H.C. Wainwright & Co. to serve as the exclusive placement agent for the offering.
Filing tone (AI): Positive
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-16. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Other reports for Acurx Pharmaceuticals, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.